IP Library Granted Patent US 8,999,377
Granted Patent B2
US 8,999,377 · App. 12/284,210 · Granted Apr 7, 2015

System for forming a biocompatible foam using polymerizable alpha(1-4)glucopyranose polymers and gas-producing component

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,377
App. No.
12/284,210
Granted
Apr 7, 2015
Kind
B2
Abstract

Biocompatible foams having excellent physical and chemical properties are described. The biocompatible foams can be formed in situ or applied as a pre-formed foam for the treatment of tissue. The invention provides biocompatible degradable foams formed with a poly-α(1→4)glucopyranose macromer. The invention also provides biostable foams formed with a poly(alkylene oxide) macromer.

Claims (37)

1. A system for forming a biocompatible biodegradable foam comprising:

a) a first covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose and pendent free-radically polymerizable groups, wherein the poly-α(1→4)glucopyranose is maltodextrin;

b) a second covalently crosslinkable polymer comprising an alkylene oxide polymer comprising pendent polymerizable groups;

c) a polymerization initiator; and

d) a gas-producing component comprising a bicarbonate salt and a biocompatible acid.

2. The system of claim 1 wherein the polymerizable groups are pendent from the poly-α(1→4)glucopyranose in an amount in the range of 0.05 mmol/gram to 0.4 mmol/gram (polymerizable groups/poly-α(1→4)glucopyranose).

3. The system of claim 2 wherein the polymerizable groups are pendent from the poly-α(1→4)glucopyranose in an amount in the range of 0.1 mmol/gram to about 0.35 mmol/gram (polymerizable groups/poly-α(1→4)glucopyranose).

4. The system of claim 1 wherein the covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose has a molecular weight of 500,000 Da or less.

5. The system of claim 1 having a ratio of the first covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose to the second covalently crosslinkable polymer in the range of 1:1 to 3:1 by weight.

6. The system of claim 1 wherein the polymerization initiator comprises a peroxide-based initiator.

7. The system of claim 1 further comprising a poloxamer surfactant.

8. The system of claim 1 comprising a first liquid composition in which the covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose is present at a concentration in the range of 200 mg/mL to 1000 mg/mL.

9. The system of claim 8 wherein the covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose is present at a concentration in the range of 400 mg/mL to 700 mg/mL.

10. The system of claim 1 comprising a first liquid composition comprising a first member of a redox pair at a concentration in the range of 2.0 mM to 25 mM.

11. The system of claim 1 comprising a first liquid composition comprising the biocompatible acid at a concentration in the range of 20 mg/mL to 80 mg/mL.

12. The system of claim 1 comprising a second liquid composition comprising a second member of a redox pair at a concentration in the range of 2.0 mM to 25 mM.

13. The system of claim 1 comprising a second liquid composition comprising the bicarbonate salt at a concentration in the range of 20 mg/mL to 80 mg/mL.

14. The system of claim 1 comprising a second liquid composition including the second covalently crosslinkable polymer at a concentration in the range of 100 mg/mL to 500 mg/mL.

15. The system of claim 1 comprising a first liquid composition comprising ferrous lactate at a concentration in the range of 4 mM to 30 mM, citric acid at a concentration in the range of 60 mg/mL to 120 mg/mL, and the covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose and pendent polymerizable groups at a concentration in the range of 500 mg/mL to 700 mg/mL, and a second liquid composition comprising hydrogen peroxide at a concentration in the range of 4 mM to 30 mM, potassium bicarbonate at a concentration in the range of 60 mg/mL to 120 mg/mL, and the second covalently crosslinkable polymer at a concentration in the range of 350 mg/mL to 550 mg/mL.

16. The system of claim 1 wherein the pendent free radically polymerizable groups are selected from the group consisting of acrylate, methacrylate, ethacrylate, 2-phenyl acrylate, acrylamide, methacrylamide, itaconate groups, and styrene.

17. The system of claim 1 wherein the polymerization initiator comprises an activating component that is a Fe 2+ -based activator.

18. The system of claim 17 wherein the polymerization initiator comprises an activating component selected from the group consisting of ferrous gluconate, ferrous ascorbate, ferrous acetylacetonate, and ferrous lactate.

19. The system of claim 1 wherein the system comprises an aqueous liquid, and the first and second covalently crosslinkable polymers, the polymerization initiator, and the gas-producing component are dissolvable in the aqueous liquid.

20. A system for forming a biocompatible biodegradable foam comprising:

a) a first covalently crosslinkable polymer comprising a linear poly-α(1→4)glucopyranose having a molecular weight of 500,000 Da or less and comprising pendent free radically polymerizable groups;

b) a second covalently crosslinkable polymer comprising an alkylene oxide polymer comprising pendent polymerizable groups;

c) a Fe 2+ -based activator;

d) a biocompatible acid; and

e) a bicarbonate salt.

21. A system for forming a biocompatible biodegradable foam comprising:

a) a first covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose and pendent free-radically polymerizable groups;

b) a second covalently crosslinkable polymer comprising an alkylene oxide polymer comprising pendent polymerizable groups;

c) a polymerization initiator; and

d) a water-soluble gas-producing component comprising a bicarbonate salt and a biocompatible acid;

wherein the first and second covalently crosslinkable polymers, polymerization initiator, and gas-producing component are dissolvable in a physiologically compatible aqueous composition having a pH in the range of about 6.5 to about 7.5.

22. The system of claim 21 wherein the water-soluble gas-producing component is present in an amount sufficient to cause formation of pores in the biocompatible biodegradable foam when combined with the polymer and polymerization initiator.

23. The system of claim 21 wherein the first covalently crosslinkable polymer comprising poly-α(1→4)glucopyranose has a molecular weight of 500,000 Da or less.

Assignments (5)
SECURITY INTEREST Recorded Jan 21, 2026
From: SURMODICS COATINGS, LLC
To: BANK OF MONTREAL, AS COLLATERAL AGENT
Reel/Frame 074461/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS MD, LLC
Reel/Frame 073894/0058 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2008
From: ROLFES, EMILY R.; CHUDZIK, STEPHEN J.
To: SURMODICS, INC.
Reel/Frame 022028/0698 →